Carlson Capital L P Taysha Gene Therapies, Inc. Transaction History

Carlson Capital L P

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$0.59 - $0.87 $11,800 - $17,400	-20,000 Reduced 3.97%	484,000 $319,000
Q1 2023 May 12, 2023	SELL	$0.65 - $2.3 $36,400 - $128,799	-56,000 Reduced 10.0%	504,000 $403,000
Q4 2022 Feb 14, 2023	BUY	$1.39 - $2.98 $500,399 - $1.07 Million	360,000 Added 180.0%	560,000 $1.27 Million
Q3 2022 Nov 14, 2022	BUY	$1.76 - $4.94 $61,600 - $172,900	35,000 Added 21.21%	200,000 $386,000
Q2 2022 Aug 15, 2022	BUY	$2.47 - $6.77 $407,550 - $1.12 Million	165,000 New	165,000 $614,000

119

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $103M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Carlson Capital L P, based on Form 13F filings with the SEC.

Stay updated on Carlson Capital L P with notifications on news.